Intra-Cellular Therapies (Nasdaq: ITCI) announced the pricing of its previously announced underwritten public offering of 4,750,000 shares of its common ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE